Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076701 | 0.81 | HTR7 (0.56) | HTR7HTR1AHTR2AMEN1KMT2A | |
| SCHEMBL10801800 | 0.80 | KCNK3 (0.55) | HTR7HTR1AHTR2AKCNK3 | |
| SCHEMBL2073913 | 0.79 | HTR7 (0.69) | HTR7HTR1AHTR2AKCNK3 | |
| SCHEMBL2076624 | 0.77 | HTR7 (0.66) | HTR7HTR1AHTR2AMEN1KMT2A | |
| SCHEMBL2075429 | 0.76 | HTR7 (0.85) | HTR7HTR1AHTR2AMEN1KMT2A | |
| SCHEMBL10799759 | 0.75 | CREBBP (0.72) | KCNK3 | |
| SCHEMBL4419022 | 0.74 | HTR7 (0.65) | HTR7HTR1AHTR2AMEN1KMT2A | |
| SCHEMBL10806396 | 0.73 | KCNK3 (0.54) | HTR7HTR1AHTR2AKCNK3 | |
| SCHEMBL10804678 | 0.73 | HTR7 (0.64) | HTR7HTR1AHTR2AKCNK3 | |
| SCHEMBL2074615 | 0.73 | HTR7 (0.64) | HTR7HTR1AHTR2AKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | BONAVENTURE PASCAL | 2009-11-05 | — | — | US | claimed |
| EP-2052251-A1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-29 | — | — | EP | claimed |
| EP-1668014-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | claimed |
| WO-2008013556-A1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-01-31 | — | — | WO | claimed |
| EP-2052251-B1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-8883808-B2 | Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008013556-A1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-01-31 | — | — | WO | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | HTR7 17/4885HTR1A 8/4885HTR2A 9/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR7 17/4885HTR1A 8/4885HTR2A 9/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR7 17/4885HTR1A 8/4885HTR2A 9/4885 |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | HTR7, HTR1A, HTR6 | HTR7 1/4885HTR1A 2/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.